Sangamo BioSciences | SGMO - Equity Capital And Reserves


Sangamo BioSciences reported $19.6M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Alaunos Therapeutics USD 1.29M 865K Mar/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Amgen USD 11.69B 2.5B Jun/2026
Bayer EUR 29.71B 863M Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Cipla INR 344.32B 15.13B Mar/2026
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 95.35M 7.38M Mar/2026
CSL USD 18.66B 2.75B Dec/2025
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Grifols EUR 6.21B 133.12M Dec/2025
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Merck USD 41.93B 3.94B Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Omeros USD -228.68M 15.13M Jun/2025
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 69.57B 3.24B Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026